MASS vs NBIX · rev $59.6M vs P/E 45, rev $2.36B
908 Devices Inc (MASS) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
908 Devices Inc (MASS) is a medical devices company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported MASS revenue for 2024-12-31 was $59.6M. Net income was -$72.2M. Revenue was up 18.7% from 2023-12-31 to 2024-12-31. MASS currently screens at market cap $238.5M.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MASS currently screens at market cap $238.5M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MASS and NBIX stock pages for the full models.
Not investment advice.